Back to search results

Resistance Exercise Program for Breast Cancer-Related Fatigue

This study is looking at how a resistance exercise program, called Strength After Breast Cancer (SABC), can help breast cancer survivors manage fatigue. The program involves twice-weekly resistance exercises using resistance bands for 45 minutes. Researchers want to understand if factors like your socioeconomic status (your financial and social standing) and allostatic load (the wear and tear on your body from stress) affect how well you stick with the program. They also want to see how things like your confidence in exercising and support from others influence your participation. This study is currently recruiting women, aged 18 and older, who have been diagnosed with non-metastatic breast cancer (stages 0, I, II, or III) between one and three years ago. The main goal is to see how many people complete the program.

Study design
This is an interventional study planning to enroll 60 women. It is not specified if participants will be randomly assigned to different groups.
What's involved
Participants will complete twice-weekly resistance exercises for 45 minutes using resistance bands, following a physical therapy workout plan.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 3 months to measure dropout rates.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06960720

Lifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management

Recruiting
NAAges 18+InterventionalSupportive care
West Virginia University
~60 participants
Updated 2025-10-31 on ClinicalTrials.gov
What's tested:Resistance Exercises

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dropout Rate - Lower SES
Measured over 3 Months
+2 more outcomes measured

Conditions

Breast Cancer
Fatigue

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
West Virginia1

Study leadership

  • Megan Clark, MD · PRINCIPAL_INVESTIGATOR · West Virginia University

Who to contact

Megan Clark, MD
[email protected]
304-974-3912
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects must have histologically or cytologically confirmed Breast Cancer; any tumor molecular subtype can be enrolled.
Subjects must have been diagnosed with non-metastatic breast cancer, defined as stage 0, I, II, or III (according to the American Joint Committee on Cancer Tumor, Node, Metastasis staging system), and must be between one and three years post-diagnosis at the time of enrollment. With treatment being received from the West Virginia University (WVU) Cancer Institute.
Any severity or report of fatigue. This can be done through a subjective report documented by any healthcare professional or through a screening tool like the enhanced distress thermometer.
Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Subjects who are pregnant (first or second trimester) or breastfeeding must receive additional approval from their obstetrics and gynecology physician for participation. Only individuals with a singleton pregnancy (no multiple gestations) will be eligible for participation. Pregnant participants must be in their first or second trimester at the time of enrollment to ensure they can complete the full three-month program before childbirth. Multiple gestations are associated with higher risks of pregnancy complications, increased physical limitations, and a greater likelihood of preterm delivery, which may prevent completion of the program.

Exclusion

Male biological gender. Males will be excluded from the study due to the rarity of male breast cancer and the variability gender creates on AL scores.
Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, active alcoholism, or psychiatric illness/social situations that would limit compliance with study requirements.
Subjects with pregnancy beyond the second trimester at the time of enrollment, as later stages of pregnancy may prevent completion of the full three-month program.
Subjects who are pregnant with multiple gestations (e.g., twins, triplets, or higher-order pregnancies) due to the increased risk of pregnancy-related complications, physical limitations, and the likelihood of preterm delivery, which may interfere with program completion.
Subjects whose self-reported household income is above or below the median household income in Appalachia ($61,688) and for whom the target enrollment of 30 participants in that respective SES group (higher or lower) has already been met at the time of screening, as representation of both SES groups is required for the study.

What this trial measures

  • Dropout Rate - Lower SES3 Months

    Percentage of participants in the lower SES group who drop out of the program

  • Dropout Rate - Higher SES3 Months

    Percentage of participants in the higher SES group who drop out of the program

  • Overall Dropout Rate3 Months

    Percentage of participants who drop out of the program.